amlodipine has been researched along with Hyperlipemia in 21 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Single-pill amlodipine besylate/atorvastatin calcium (Caduet), Pfizer Inc, NY, USA) is the first therapy aimed at the simultaneous treatment of hypertension (HTN) and dyslipidaemia (DYS)." | 8.82 | Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. ( Cowie, MR, 2005) |
| " In addition to recommending lifestyle modifications, eight dosage strengths of amlodipine/atorvastatin single pill (5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg) were electively titrated to improve blood pressure and lipid control." | 6.71 | Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). ( Blank, R; LaSalle, J; Maroni, J; Reeves, R; Sun, F; Tarasenko, L, 2005) |
| "Single-pill amlodipine/atorvastatin was associated with significant improvements in BP, LDL-C target attainment, and 10-year CV risk in patients with uncontrolled hypertension in Slovakia." | 5.17 | Slovak trial on cardiovascular risk reduction following national guidelines with CaDUET® (the STRONG DUET study). ( Fedacko, J; Janicko, M; Jarcuska, P; Jedlickova, L; Kmec, J; Lopuchovsky, T; Merkovska, L; Pella, D; Sabol, F; Sajty, M, 2013) |
| "To explore if non-concurrent amlodipine dosing results in less drug interaction, the pharmacokinetic profiles, safety and efficacy endpoints were assessed following repeated doses of simvastatin, co-administered concurrently or non-concurrently with amlodipine in patients with coexisting hypertension and hyperlipidemia." | 5.14 | Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin. ( Choi, JW; Kim, SH; Lee, H; Lee, SJ; Lim, HE; Park, CG, 2010) |
| "Single-pill amlodipine besylate/atorvastatin calcium (Caduet), Pfizer Inc, NY, USA) is the first therapy aimed at the simultaneous treatment of hypertension (HTN) and dyslipidaemia (DYS)." | 4.82 | Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. ( Cowie, MR, 2005) |
| "Patients ≥65years-old with a diagnosis of hypertension and/or dyslipidaemia receiving treatment with Enalapril and/or Amlodipine and/or Simvastatin." | 3.96 | [Effects of changing the appearance of medications in safety and adherence in chronic patients over 65 years of age in primary care. CAMBIMED Study]. ( Arancón-Monge, JM; Campos-Díaz, L; de Castro-Cuenca, A; Del Cura-González, I; Rodríguez Barrientos, R; Serrano-Vázquez, Á, 2020) |
| "Hypertension is a highly prevalent disease and a strong risk factor for cardiovascular disease in industrialized countries in Europe and North America." | 3.83 | [Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk]. ( Kékes, E, 2008) |
| " Because of interaction between amlodipine and simvastatin, in combination with physical activity, the patient reported: muscle pain, weakness of the muscles, dizziness, and confusion." | 3.81 | [Drug interaction in 63-year-old male sportsman--a case report]. ( Foerster, J; Schetz, D; Sein Anand, J, 2015) |
| "Telmisartan exerted anti-obesity effects and restored leptin sensitivity, given as a treatment to rats with obesity." | 3.80 | Chronic blockade of angiotensin AT₁ receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats. ( Barkhausen, J; Hübel, N; Mildner, M; Müller-Fielitz, H; Raasch, W; Vogt, FM, 2014) |
| " The final population pharmacokinetic model shows that the elimination rate constant for simvastatin acid, the active form by hydrolysis of its lactone prodrug (i." | 2.79 | Genetic algorithm guided population pharmacokinetic model development for simvastatin, concurrently or non-concurrently co-administered with amlodipine. ( Chaturvedula, A; Lee, H; Sale, ME, 2014) |
| "Atorvastatin was as potent an anti-ischaemic agent as amlodipine." | 2.75 | Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering? ( Beckerman, B; Buch, J; Bultas, J; Deanfield, JE; Sellier, P; Shi, H; Thaulow, E; Yunis, C, 2010) |
| " In addition to recommending lifestyle modifications, eight dosage strengths of amlodipine/atorvastatin single pill (5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg) were electively titrated to improve blood pressure and lipid control." | 2.71 | Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). ( Blank, R; LaSalle, J; Maroni, J; Reeves, R; Sun, F; Tarasenko, L, 2005) |
| "Hypertension and dyslipidemia are highly co-prevalent, but often poorly controlled, coronary heart disease (CHD) risk factors." | 1.36 | Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice. ( Chen, L; Eaddy, M; Jackson, JH; Kean, AJ; Lunacsek, OE; Neutel, JM; Roberts, C, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Arancón-Monge, JM | 1 |
| de Castro-Cuenca, A | 1 |
| Serrano-Vázquez, Á | 1 |
| Campos-Díaz, L | 1 |
| Rodríguez Barrientos, R | 1 |
| Del Cura-González, I | 1 |
| Cheung, DWS | 1 |
| Koon, JCM | 1 |
| Wong, PH | 1 |
| Yau, KC | 1 |
| Wat, ECL | 1 |
| Chan, JYW | 1 |
| Lau, VKM | 1 |
| Ko, ECH | 1 |
| Waye, MMY | 1 |
| Fung, KP | 1 |
| Dhruva, SS | 1 |
| Huang, C | 1 |
| Spatz, ES | 1 |
| Coppi, AC | 1 |
| Warner, F | 1 |
| Li, SX | 1 |
| Lin, H | 1 |
| Xu, X | 1 |
| Furberg, CD | 1 |
| Davis, BR | 2 |
| Pressel, SL | 2 |
| Coifman, RR | 1 |
| Krumholz, HM | 1 |
| Chaturvedula, A | 1 |
| Sale, ME | 1 |
| Lee, H | 2 |
| Müller-Fielitz, H | 1 |
| Hübel, N | 1 |
| Mildner, M | 1 |
| Vogt, FM | 1 |
| Barkhausen, J | 1 |
| Raasch, W | 1 |
| Schetz, D | 1 |
| Foerster, J | 1 |
| Sein Anand, J | 1 |
| Veeraputhiran, M | 1 |
| Sundermeyer, M | 1 |
| Kékes, E | 1 |
| Deanfield, JE | 1 |
| Sellier, P | 1 |
| Thaulow, E | 1 |
| Bultas, J | 1 |
| Yunis, C | 1 |
| Shi, H | 1 |
| Buch, J | 1 |
| Beckerman, B | 1 |
| Neutel, JM | 1 |
| Eaddy, M | 1 |
| Lunacsek, OE | 1 |
| Roberts, C | 1 |
| Chen, L | 1 |
| Kean, AJ | 1 |
| Jackson, JH | 1 |
| Park, CG | 1 |
| Choi, JW | 1 |
| Lee, SJ | 1 |
| Kim, SH | 1 |
| Lim, HE | 1 |
| Fedacko, J | 1 |
| Pella, D | 1 |
| Jarcuska, P | 1 |
| Sabol, F | 1 |
| Kmec, J | 1 |
| Lopuchovsky, T | 1 |
| Merkovska, L | 1 |
| Jedlickova, L | 1 |
| Janicko, M | 1 |
| Sajty, M | 1 |
| Leibovitz, E | 1 |
| Beniashvili, M | 1 |
| Zimlichman, R | 1 |
| Freiman, A | 1 |
| Shargorodsky, M | 1 |
| Gavish, D | 1 |
| Wimett, L | 1 |
| Laustsen, G | 1 |
| Ito, A | 1 |
| Fukumoto, Y | 1 |
| Shimokawa, H | 1 |
| Brock, CM | 1 |
| Pitcock, J | 1 |
| Blank, R | 1 |
| LaSalle, J | 1 |
| Reeves, R | 1 |
| Maroni, J | 1 |
| Tarasenko, L | 1 |
| Sun, F | 1 |
| Cowie, MR | 1 |
| Barzilay, JI | 1 |
| Cutler, JA | 1 |
| Whelton, PK | 1 |
| Basile, J | 1 |
| Margolis, KL | 1 |
| Ong, ST | 1 |
| Sadler, LS | 1 |
| Summerson, J | 1 |
| De la Figuera von Wichmann, M | 1 |
| Llisterri Caro, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double Blind Atorvastatin Amlodipine Study (DUAAL) Effect Of Amlodipine, Atorvastatin And The Combination On Transient Myocardia Ischemia In Coronary Artery Disease.[NCT00159718] | Phase 4 | 360 participants | Interventional | 2001-07-31 | Completed | ||
| Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension[NCT01238705] | Phase 4 | 280 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for amlodipine and Hyperlipemia
| Article | Year |
|---|---|
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvast | 2008 |
A closer look at Caduet. The new generation of combination treatment.
Topics: Amlodipine; Drug Combinations; Drug Costs; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; P | 2005 |
Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases | 2005 |
[Overview of cardiovascular risk factors].
Topics: Age Factors; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; As | 2006 |
8 trials available for amlodipine and Hyperlipemia
| Article | Year |
|---|---|
Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Topics: Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Cardiovascular Dise | 2017 |
Genetic algorithm guided population pharmacokinetic model development for simvastatin, concurrently or non-concurrently co-administered with amlodipine.
Topics: Adult; Aged; Algorithms; Amlodipine; Drug Interactions; Drug Therapy, Combination; Female; Humans; H | 2014 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvast | 2008 |
Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?
Topics: Aged, 80 and over; Amlodipine; Angina, Stable; Antihypertensive Agents; Atorvastatin; Chronic Diseas | 2010 |
Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Area Under Curve; Drug Administration Schedule; Dr | 2010 |
Slovak trial on cardiovascular risk reduction following national guidelines with CaDUET® (the STRONG DUET study).
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Drug Combinations; Female; Hepta | 2013 |
Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study).
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atorvastatin; Drug Combinations | 2005 |
Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHA
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; | 2006 |
10 other studies available for amlodipine and Hyperlipemia
| Article | Year |
|---|---|
[Effects of changing the appearance of medications in safety and adherence in chronic patients over 65 years of age in primary care. CAMBIMED Study].
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Chronic Disease; Drug Labeling; Drug P | 2020 |
Combination of atorvastatin or hydrochlorothiazide/amlodipine with
Topics: Amlodipine; Atherosclerosis; Atorvastatin; Drugs, Chinese Herbal; Humans; Hydrochlorothiazide; Hyper | 2021 |
Chronic blockade of angiotensin AT₁ receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Obesity Agents; Antihypertensive | 2014 |
[Drug interaction in 63-year-old male sportsman--a case report].
Topics: Amlodipine; Confusion; Dizziness; Drug Interactions; Exercise; Humans; Hyperlipidemias; Hypertension | 2015 |
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensiv | 2008 |
Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Calcium | 2010 |
Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Arteries; Atorvastatin; Biomark | 2003 |
Amlodipine/atorvastatin (Caduet).
Topics: Amlodipine; Angina Pectoris; Atorvastatin; Clinical Trials as Topic; Dose-Response Relationship, Dru | 2004 |
Caduet treats two cardiovascular conditions at once.
Topics: Amlodipine; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Heptanoic Acids; Human | 2004 |
Changing characteristics of patients with vasospastic angina in the era of new calcium channel blockers.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris, Variant; Ca | 2004 |